不可思議的營養醫學~誰說生病一定要用藥醫!!

immunoceuticals可視為物質的免疫治療療效內服。已經取得了超過50種蘑菇，表現出在體外或動物模型，這些潛在的抗癌活性immunoceuticals，有6個被調查在人類癌症。全部是無毒的，很好的耐受性。香菇多醣和裂褶很少有口頭的活動。主動己糖相關化合物（AHCC）定義不清，但已顯示出早期臨床的承諾。舞茸D-組分具有證明臨床療效有限，但對照研究正在進行。 PSK（多醣 - K）和PSP（多醣肽 - - 兩個雲芝糖蛋白。自1970年以來的最有希望在日本試驗已經證明，雲芝顯著延長五年或以後在胃癌，結腸癌，直腸癌症的生存，食管，鼻咽，肺（非小細胞類型），並在HLA B40陽性乳腺癌的子集。PSP的二期和三期試驗在中國。在雙盲試驗中，PSP的顯著延長五年在食管癌的生存。PSP顯著地改善生活質量，提供了大量的緩解疼痛，免疫狀態和增強胃的癌症患者在70-97％，食道癌，肺癌，卵巢癌，宮頸癌。PSK和PSP的增強免疫細胞的生產改進的化療症狀，增強樹突狀細胞毒性T細胞的浸潤。他們的耐受性非常高，生存和生活質量，並與化療和放射治療的兼容性成熟的好處，使它們適合癌症管理方案。

Immunoceuticals can be considered as substances having immunotherapeutic efficacy when taken orally. More than 50 mushroom species have yielded potential immunoceuticals that exhibit anticancer activity in vitro or in animal models and of these, six have been investigated in human cancers. All are non-toxic and very well tolerated. Lentinan and schizophyllan have little oral activity. Active Hexose Correlated Compound (AHCC) is poorly defined but has shown early clinical promise. Maitake D-Fraction has limited proof of clinical efficacy to date, but controlled research is underway. Two proteoglycans from Coriolus versicolor - PSK (Polysaccharide-K) and PSP (Polysaccharide-Peptide - have demonstrated the most promise. In Japanese trials since 1970, PSK significantly extended survival at five years or beyond in cancers of the stomach, colon-rectum, esophagus, nasopharynx, and lung (non-small cell types), and in a HLA B40-positive breast cancer subset. PSP was subjected to Phase II and Phase III trials in China. In double-blind trials, PSP significantly extended five-year survival in esophageal cancer. PSP significantly improved quality of life, provided substantial pain relief, and enhanced immune status in 70-97 percent of patients with cancers of the stomach, esophagus, lung, ovary, and cervix. PSK and PSP boosted immune cell production, ameliorated chemotherapy symptoms, and enhanced tumor infiltration by dendritic and cytotoxic T-cells. Their extremely high tolerability, proven benefits to survival and quality of life, and compatibility with chemotherapy and radiation therapy makes them well suited for cancer management regimens.

文獻資料:Altern Med Rev. 2000;5(1):4-27.